4886 ASKA Pharmaceutical Holdings Co.,Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4886

TSE Prime

ASKA Pharmaceutical Holdings Co.,Ltd.

1,929

JPY

-37

(-1.88%)

Dec 5, 3:30 pm JST

12.47

USD

Dec 5, 1:30 am EST

Result

PTS

outside of trading hours

1,932.1

Dec 5, 3:24 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2022	56,607	4,795	4,880	4,290	151.2	15	May 12, 2022	J-GAAP
Mar, 2023	60,461	5,108	5,232	4,238	150.1	16	May 11, 2023	J-GAAP
Mar, 2024	62,843	6,500	6,522	7,545	266.5	40	May 10, 2024	J-GAAP
Mar, 2025	64,139	5,331	5,107	5,101	180.0	55	May 12, 2025	J-GAAP
Mar, 2026 Guidance	71,000	6,000	6,000	5,000	176.1	55	Nov 4, 2025	J-GAAP
YoY	+10.7%	+12.5%	+17.5%	-2.0%	-2.2%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2021	May 12, 2020	53,000	2,000	1,900	1,500	14	J-GAAP
	Feb 1, 2021	54,000	2,800	2,100	1,900	14	J-GAAP
	Apr 23, 2021	55,100	3,600	3,000	2,700	14	J-GAAP
Results	May 11, 2021	55,181	3,609	3,092	2,713	14	J-GAAP
Mar, 2022	May 11, 2021	Available in future release
	Sep 27, 2021
	Dec 20, 2021
	Mar 28, 2022
Results	May 12, 2022
Mar, 2023	May 12, 2022
	Nov 7, 2022
Results	May 11, 2023
Mar, 2024	May 11, 2023
	Sep 25, 2023
	Nov 6, 2023
Results	May 10, 2024
Mar, 2025	May 10, 2024
Results	May 12, 2025
Mar, 2026	May 12, 2025	75,000	6,800	6,800	5,200	55	J-GAAP
	Nov 4, 2025	71,000	6,000	6,000	5,000	55	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2001	23,537	+0.9	Available in future release
Mar, 2002	22,448	-4.6
Mar, 2003	21,157	-5.8
Mar, 2004	20,188	-4.6
Mar, 2005	20,635	+2.2
Mar, 2006	23,927	+16.0
Mar, 2007	30,301	+26.6
Mar, 2008	30,170	-0.4
Mar, 2009	30,422	+0.8
Mar, 2010	35,784	+17.6
Mar, 2011	45,849	+28.1
Mar, 2012	40,637	-11.4
Mar, 2013	40,963	+0.8
Mar, 2014	39,501	-3.6
Mar, 2015	42,907	+8.6
Mar, 2016	43,215	+0.7
Mar, 2017	48,527	+12.3
Mar, 2018	48,944	+0.9
Mar, 2019	46,706	-4.6
Mar, 2020	52,542	+12.5
Mar, 2021	55,181	+5.0
Mar, 2022	56,607	+2.6
Mar, 2023	60,461	+6.8
Mar, 2024	62,843	+3.9
Mar, 2025	64,139	+2.1
Mar, 2026 Guidance	71,000	+10.7	6,000	+12.5	6,000	+17.5	176.1	-2.2

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2024	62,843	6,500	10.3	12.96	8.48	0.71	266.5
Mar, 2025	64,139	5,331	8.31	8.02	5.24	0.66	180.0
Mar, 2026 Guidance	71,000	6,000	8.45	7.48	4.60	0.65	176.1

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	64,139	6,500	6,522	7,545	266.5
Fiscal Year	Mar, 2025	Mar, 2024	Mar, 2024	Mar, 2024	Mar, 2024

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2022	30,289	2,229	2,245	1,892	67.0	8	May 11, 2023	J-GAAP
Oct - Mar, 2023	31,195	3,445	3,426	3,416	120.7	20	May 10, 2024	J-GAAP
Oct - Mar, 2024	31,768	1,986	1,795	2,541	89.6	30	May 12, 2025	J-GAAP
Oct - Mar, 2025 Guidance	35,747	3,351	3,340	2,774	97.7	28	Nov 4, 2025	J-GAAP
YoY	+12.5%	+68.7%	+86.1%	+9.2%	+9.0%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2023	5,108	2,225	3,351	-1,126	-1,820	17,505	20.09	J-GAAP
Mar, 2024	6,500	3,192	1,486	1,706	-3,943	16,738	18.45	J-GAAP
Mar, 2025	5,331	-3,639	2,485	-6,124	-2,956	10,603	10.21	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2023	31,648	3,055	3,096	4,129	145.9	47.5	Nov 6, 2023	J-GAAP
Apr - Sep, 2024	32,371	3,345	3,312	2,560	90.4	64.9	Nov 5, 2024	J-GAAP
Apr - Sep, 2025	35,253	2,649	2,660	2,226	78.5	44.3	Nov 4, 2025	J-GAAP
YoY	+8.9%	-20.8%	-19.7%	-13.0%	-13.1%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	17,176	2,471	2,535	2,329	82.3	14.4	Feb 5, 2024	J-GAAP
Jan - Mar, 2024	14,019	974	891	1,087	38.4	6.9	May 10, 2024	J-GAAP
Apr - Jun, 2024	16,352	1,758	1,813	1,273	45.0	10.8	Aug 5, 2024	J-GAAP
Jul - Sep, 2024	16,019	1,587	1,499	1,287	45.4	9.9	Nov 5, 2024	J-GAAP
Oct - Dec, 2024	17,555	2,150	2,134	1,538	54.3	12.2	Feb 3, 2025	J-GAAP
Jan - Mar, 2025	14,213	-164	-339	1,003	35.4	-1.2	May 12, 2025	J-GAAP
Apr - Jun, 2025	17,641	1,479	1,620	1,244	43.9	8.4	Aug 4, 2025	J-GAAP
Jul - Sep, 2025	17,612	1,170	1,040	982	34.6	6.6	Nov 4, 2025	J-GAAP
YoY	+9.9%	-26.3%	-30.6%	-23.7%	-23.8%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2020	15,947	+9.0	Available in future release
Jan - Mar, 2021	11,831	+4.4
Apr - Jun, 2021	14,221	+3.7
Jul - Sep, 2021	14,256	+4.1
Oct - Dec, 2021	15,702	-1.5
Jan - Mar, 2022	12,428	+5.0
Apr - Jun, 2022	15,269	+7.4
Jul - Sep, 2022	14,903	+4.5
Oct - Dec, 2022	17,087	+8.8
Jan - Mar, 2023	13,202	+6.2
Apr - Jun, 2023	16,023	+4.9
Jul - Sep, 2023	15,625	+4.8
Oct - Dec, 2023	17,176	+0.5
Jan - Mar, 2024	14,019	+6.2
Apr - Jun, 2024	16,352	+2.1
Jul - Sep, 2024	16,019	+2.5
Oct - Dec, 2024	17,555	+2.2
Jan - Mar, 2025	14,213	+1.4
Apr - Jun, 2025	17,641	+7.9
Jul - Sep, 2025	17,612	+9.9	1,170	-26.3	1,040	-30.6	34.6	-23.8

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	17,641	2,471	2,535	6,878	242.2
Fiscal Year	Jun, 2025	Dec, 2023	Dec, 2023	Dec, 2021	Dec, 2021

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2023	1,928.14	62.6	87,138	54,533	49,619	0.23	May 11, 2023	J-GAAP
Mar, 2024	2,186.10	68.2	90,745	61,930	56,372	0.15	May 10, 2024	J-GAAP
Mar, 2025	2,302.61	62.9	103,889	65,310	59,545	0.17	May 12, 2025	J-GAAP
Apr - Sep, 2025	ー	61.5	108,773	66,856	60,921	0.19	Nov 4, 2025	J-GAAP

ASKA Pharmaceutical Holdings Co.,Ltd.(4886) Financial Results